Quantification of the Glycemic Response to Microdoses of Subcutaneous Glucagon at Varying Insulin Levels
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon delivery in closed-loop control of type 1 diabetes is effective in minimizing hypoglycemia. However, high insulin concentration lowers the hyperglycemic effect of glucagon, and small doses of glucagon in this setting are ineffective. There are no studies clearly defining the relationship between insulin levels, subcutaneous glucagon, and blood glucose. RESEARCH DESIGN AND METHODS: Using a euglycemic clamp technique in 11 subjects with type 1 diabetes, we examined endogenous glucose production (EGP) of glucagon (25, 75, 125, and 175 μg) at three insulin infusion rates (0.016, 0.032, and 0.05 units/kg/h) in a randomized, crossover study. Infused 6,6-dideuterated glucose was measured every 10 min, and EGP was determined using a validated glucoregulatory model. Area under the curve (AUC) for glucose production was the primary outcome, estimated over 60 min. RESULTS: At low insulin levels, EGP rose proportionately with glucagon dose, from 5 ± 68 to 112 ± 152 mg/kg (P = 0.038 linear trend), whereas at high levels, there was no increase in glucose output (19 ± 53 to 26 ± 38 mg/kg, P = NS). Peak glucagon serum levels and AUC correlated well with dose (r2 = 0.63, P < 0.001), as did insulin levels with insulin infusion rates (r2 = 0.59, P < 0.001). CONCLUSIONS: EGP increases steeply with glucagon doses between 25 and 175 μg at lower insulin infusion rates. However, high insulin infusion rates prevent these doses of glucagon from significantly increasing glucose output and may reduce glucagon effectiveness in preventing hypoglycemia when used in the artificial pancreas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60591-7 · Cited by 2,931
Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes
Hovorka, R., Canonico, V., Chassin, L. J., Haueter, U., Massi-Benedetti, M., Federici, M. O., Pieber, T. R., Schaller, H. C., Schaupp, L., Vering, T., et al. (2004) · Physiological Measurement · doi:10.1088/0967-3334/25/4/010 · Cited by 1,274
Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Diabetes: Models, Signals, and Control
Cobelli, C., Dalla Man, C., Sparacino, G., Magni, L., De Nicolao, G., & Kovatchev, B. P. (2009) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2009.2036073 · Cited by 511
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Physiologic action of glucagon on liver glucose metabolism
Ramnanan, C. J., Edgerton, D. S., Kraft, G., & Cherrington, A. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01454.x · Cited by 293 · cited 1×
“Cherrington and colleagues (40) defined the action of intravenously delivered glucagon in the ca-”
BackgroundToffolo, G., Bergman, R. N., Finegood, D. T., Bowden, C. R., & Cobelli, C. (1980) · Diabetes · doi:10.2337/diab.29.12.979 · Cited by 292
Hovorka, R., Kumareswaran, K., Harris, J., Allen, J. M., Elleri, D., Xing, D., Kollman, C., Nodale, M., Murphy, H. R., Dunger, D. B., et al. (2011) · BMJ · doi:10.1136/bmj.d1855 · Cited by 244
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242 · cited 2×
“cause of reduced glucagon effectiveness (7).”
BackgroundNovel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Self-citation
Cited by
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115
“This is in particular important for prevailing insulin levels, as high insulin concentrations have been shown to partially prevent glucagon from increasing endogenous glucose production and thereby affecting glucagon efficacy (29).”
BackgroundJacobs, P. G., Resalat, N., El Youssef, J., Reddy, R., Branigan, D., Preiser, N., Condon, J., & Castle, J. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815609371 · Cited by 105
Self-citationRanjan, A., Schmidt, S., Damm-Frydenberg, C., Steineck, I., Clausen, T. R., Holst, J. J., Madsbad, S., & Nørgaard, K. (2017) · Diabetes Care · doi:10.2337/dc16-1472 · Cited by 89
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39
Hövelmann, U., Olsen, M. B., Mouritzen, U., Lamers, D., Kronshage, B., & Heise, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13562 · Cited by 28
Wendt, S. L., Ranjan, A., Møller, J. K., Schmidt, S., Knudsen, C. B., Holst, J. J., Madsbad, S., Madsen, H., Nørgaard, K., & Jørgensen, J. B. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817693254 · Cited by 20
Modeling Glucagon Action in Patients With Type 1 Diabetes
Emami, A., Youssef, J. E., Rabasa-Lhoret, R., Pineau, J., Castle, J. R., & Haidar, A. (2017) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2016.2593630 · Cited by 20
Self-citation
Metadata
- Authors
- El Youssef, J., Castle, J. R., Bakhtiani, P. A., Haidar, A., Branigan, D. L., Breen, M., & Ward, W. K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-10-10
- Volume
- 37
- Issue
- 11
- Pages
- 3054-3060
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1965308157
- Cited by
- 52
- References
- 16
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.